KDM1A抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using KDM1A mouse mAb against K562 (1), Jurkat (2), and Hela (3) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of HL-7702 cells using KDM1A mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Immunofluorescence analysis of MCF-7 cells using KDM1A mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using KDM1A mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using KDM1A mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissues using KDM1A mouse mAb with DAB staining.    

  
  

The KDM1A antibody is a crucial tool in epigenetic research, targeting the lysine-specific demethylase 1A (KDM1A/LSD1), a flavin-dependent enzyme that removes methyl groups from histone H3 lysine 4 (H3K4) and lysine 9 (H3K9). Discovered in 2004. KDM1A regulates gene expression by modifying chromatin structure, playing roles in cell differentiation, proliferation, and oncogenesis. It interacts with transcriptional repressors (e.g., CoREST) and activators, enabling context-dependent gene silencing or activation. Dysregulation of KDM1A is linked to cancers, neurological disorders, and developmental defects, making it a therapeutic target.

KDM1A antibodies are widely used in techniques like Western blotting, immunohistochemistry, ChIP-seq, and immunofluorescence to study its expression, localization, and molecular interactions. High-quality antibodies must demonstrate specificity, as KDM1A shares structural homology with other amine oxidases. Validated antibodies help explore its role in stem cell biology, cancer metastasis, and neurodegenerative diseases. Recent studies also highlight its involvement in immune regulation and metabolic pathways.

Commercial KDM1A antibodies are typically raised against epitopes in its N-terminal SWIRM domain, C-terminal amine oxidase domain, or unique peptide sequences. Researchers prioritize antibodies verified in knockout models or siRNA-treated cells to avoid cross-reactivity. As KDM1A inhibitors enter clinical trials, reliable antibodies remain essential for biomarker analysis and mechanistic studies, underscoring their significance in both basic research and translational medicine.